Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients

{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2023, 3, 16]], 'date-time': '2023-03-16T12:51:00Z', 'timestamp': 1678971060070}, 'posted': {'date-parts': [[2020, 9, 24]]}, 'group-title': 'Gastroenterology', 'reference-count': 13, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 9, 24]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Famotidine ' 'has been posited as a potential treatment for COVID-19. We compared the incidence of COVID-19 ' 'outcomes (i.e., death; and death or intensive services use) among hospitalized famotidine ' 'users vs. proton pump inhibitors (PPIs) users, hydroxychloroquine users or famotidine ' 'non-users separately.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We ' 'constructed a retrospective cohort study using data from COVID-19 Premier Hospital electronic ' 'health records. Study population were COVID-19 hospitalized patients aged 18 years or older. ' 'Famotidine, PPI and hydroxychloroquine exposure groups were defined as patients dispensed any ' 'medication containing one of the three drugs on the day of admission. The famotidine non-user ' 'group was derived from the same source population with no history of exposure to any drug ' 'with famotidine as an active ingredient prior to or on the day of admission. Time-at-risk was ' 'defined based on the intention-to-treat principle starting 1 day after admission to 30 days ' 'after admission. For each study comparison group, we fit a propensity score (PS) model ' 'through large-scale regularized B logistic regression. The outcome was modeled using a ' 'survival model.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We ' 'identified 2193 users of PPI, 5950 users of the hydroxychloroquine, 1816 users of famotidine ' 'and 26,820 non-famotidine users. After PS stratification, the hazard ratios for death were as ' 'follows: famotidine vs no famotidine HR 1.03 (0.89-1.18); vs PPIs: HR 1.14 (0.94-1.39); vs ' 'hydroxychloroquine:1.03 (0.85-1.24). Similar results were observed for the risk of death or ' 'intensive services ' 'use.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>We found no ' 'evidence of a reduced risk of COVID-19 outcomes among hospitalized COVID-19 patients who used ' 'famotidine compared to those who did not or compared to PPI or hydroxychloroquine ' 'users.</jats:p></jats:sec>', 'DOI': '10.1101/2020.09.23.20199463', 'type': 'posted-content', 'created': {'date-parts': [[2020, 9, 24]], 'date-time': '2020-09-24T15:00:17Z', 'timestamp': 1600959617000}, 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': 'Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients', 'prefix': '10.1101', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-6976-2594', 'authenticated-orcid': False, 'given': 'Azza', 'family': 'Shoaibi', 'sequence': 'first', 'affiliation': []}, {'given': 'Stephen', 'family': 'Fortin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rachel', 'family': 'Weinstein', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9810-745X', 'authenticated-orcid': False, 'given': 'Jesse A.', 'family': 'Berlin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Patrick', 'family': 'Ryan', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021021109351118000_2020.09.23.20199463v1.1', 'doi-asserted-by': 'crossref', 'unstructured': 'Malone RW , Tisdall P , Fremont-Smith P , et al. COVID-19: Famotidine, ' 'histamine, mast cells, and mechanisms. 2020.', 'DOI': '10.21203/rs.3.rs-30934/v1'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.2', 'doi-asserted-by': 'crossref', 'first-page': '36', 'DOI': '10.1016/S0149-2918(96)80177-9', 'article-title': 'The tolerability and safety profile of famotidine', 'volume': '18', 'year': '1996', 'journal-title': 'Clinical therapeutics'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.3', 'doi-asserted-by': 'publisher', 'DOI': '10.23812/Editorial-Conti-3'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.4', 'doi-asserted-by': 'crossref', 'unstructured': 'Wu C , Liu Y , Yang Y , et al. Analysis of therapeutic targets for ' 'SARS-CoV-2 and discovery of potential drugs by computational methods. ' 'Acta Pharmaceutica Sinica B 2020.', 'DOI': '10.1016/j.apsb.2020.02.008'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.5', 'first-page': 'PL365', 'article-title': 'The effect of histamine type 2 receptor antagonists on human ' 'immunodeficiency virus (HIV) replication: identification of a new class ' 'of antiviral agents', 'volume': '59', 'year': '1996', 'journal-title': 'Life sciences'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.6', 'doi-asserted-by': 'crossref', 'unstructured': 'Freedberg DE , Conigliaro J , Wang TC , et al. Famotidine use is ' 'associated with improved clinical outcomes in hospitalized COVID-19 ' 'patients: A propensity score matched retrospective cohort study. ' 'Gastroenterology 2020.', 'DOI': '10.1053/j.gastro.2020.05.053'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.7', 'doi-asserted-by': 'crossref', 'unstructured': 'Mather JF , Seip RL , McKay RG . Impact of Famotidine Use on Clinical ' 'Outcomes of Hospitalized Patients With COVID-19. Official journal of the ' 'American College of Gastroenterology| ACG 2020.', 'DOI': '10.14309/ajg.0000000000000832'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.8', 'doi-asserted-by': 'crossref', 'unstructured': 'Janowitz T , Gablenz E , Pattinson D , et al. Famotidine use and ' 'quantitative symptom tracking for COVID-19 in non-hospitalised patients: ' 'a case series. Gut 2020.', 'DOI': '10.1158/1557-3265.COVID-19-S04-01'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.9', 'doi-asserted-by': 'crossref', 'unstructured': 'Cheung KS , Hung IF , Leung WK . Association between famotidine use and ' 'COVID-19 severity in Hong Kong: a territory-wide study. Gastroenterology ' '2020.', 'DOI': '10.1053/j.gastro.2020.05.098'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.10', 'unstructured': 'Premier Healthcare Database: Data That Informs and Performs. Premier ' 'website. ' 'https://products.premierinc.com/downloads/PremierHealthcareDatabaseWhitepaper.pdf..'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.11', 'first-page': '11', 'article-title': 'A tool for assessing the feasibility of comparative effectiveness ' 'research', 'volume': '2013', 'year': '2013', 'journal-title': 'Comp Eff Res'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.12', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/03610910902859574'}, { 'key': '2021021109351118000_2020.09.23.20199463v1.13', 'doi-asserted-by': 'crossref', 'first-page': '1816', 'DOI': '10.1016/S0140-6736(19)32317-7', 'article-title': 'Comprehensive comparative effectiveness and safety of first-line ' 'antihypertensive drug classes: a systematic, multinational, large-scale ' 'analysis', 'volume': '394', 'year': '2019', 'journal-title': 'The Lancet'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2020.09.23.20199463', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 2, 15]], 'date-time': '2021-02-15T03:30:53Z', 'timestamp': 1613359853000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2020.09.23.20199463'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 9, 24]]}, 'references-count': 13, 'URL': 'http://dx.doi.org/10.1101/2020.09.23.20199463', 'relation': {}, 'published': {'date-parts': [[2020, 9, 24]]}, 'subtype': 'preprint'}